PRL-295
PRL-295 is an orally active inhibitor targeting Keap1-Nrf2 interaction. PRL-295 increases the thermal stability of Keap1 and disrupts its interaction with Nrf2, thereby activating the Nrf2-dependent transcriptional target NAD (P) H:quinone oxidoreductase 1 (NQO1). PRL-295 protects against Acetaminophen -induced liver injury in mice[1].
Product Specifications
CAS Number
2377770-85-7
UNSPSC
12352005
Target
Aminotransferases (Transaminases) ; Keap1-Nrf2; Quinone Reductase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease; NF-κB
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/prl-295.html
Smiles
O=C(CN(S(=O)(C1=CC=C(C=C1)OC)=O)C2=NC=C(N(S(=O)(C3=CC=C(C=C3)OC)=O)CC(F)(F)F)C4=C2C=CC=C4)O
Molecular Formula
C27H24F3N3O8S2
Molecular Weight
639.62
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker) (MUC1/2278R), CF594 conjugate, 0.1mg/mL
